Breast Cancer

Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.

Patients with breast cancer who experience adjuvant hormone therapy (AHT)-related hot flashes and are treated for hot flashes at the beginning of therapy had worse outcomes than those who did not.

Facility characteristics at community-based breast imaging facilities may be linked to screening disparities across ethnic and racial groups.

The NCCN guidelines have been amended to include trastuzumab deruxtecan for use in patients with HER2-low metastatic breast cancer and sacituzumab govitecan for use in patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.

At the 2022 Supportive Care in Cancer Annual Meeting, Jeffrey Crawford, MD, highlighted the potential value of biosimilars in reducing gaps in care for the treatment of febrile neutropenia.

Approximately 140 in 100,000 pregnant women receive a cancer diagnosis. Of these diagnoses, 0.1% are considered malignant tumors.

Aliènne Salleroli, MS, BSN, RN, OCN, underscores the importance of open dialogue surrounding diversity, equity, and inclusion in oncology leadership.

Patients with hormone receptor¬–positive, HER2-negative, node-positive high-risk early breast cancer who have certain characteristics may benefit from early dose adjustments with adjuvant abemaciclib.

Patients with early-stage breast cancer who have low vitamin D counts may be at risk of developing chemotherapy-induced peripheral neuropathy.

Reducing ribociclib dosing by 200 mg or 400 mg did not affect overall survival in patients with hormone receptor–positive, HER2-negative, advanced breast cancer.

Findings from DESTINY-Breast04 (NCT03734029) support the use of trastuzumab deruxtecan in patients with hormone receptor–positive, HER2-low metastatic breast cancer.

Updated safety findings from DESTINY-Breast03 showed that treatment with trastuzumab deruxtecan was safe and tolerable for patients with HER2-positive metastatic breast cancer.

Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Although 83% of Black patients with metastatic breast cancer expressed interest in clinical trials, only 40% reported having a conversation about enrollment with their health care provider, highlighting one of many potential barriers to achieving clinical trial diversity.

Kellie Zeichner, RN, BSN, OCN, discusses the production of biosimilars, their approval and naming processes, and why immunogenicity is important when discussing these agents.

Sacituzumab govitecan-hziy significantly improved progression-free survival in patients with HER2-low expressing TNBC and HER2-negative disease.

Current ASCO guidelines recommend that providers discuss the possibility of infertility with their patients as soon as possible before treatment begins.

Entrectinib elicited encouraging responses in patients with breast cancer that harbors NTRK fusions, according to updates from the phase 2 STARTRK-2 trial.

Patients with HER2-positive breast cancer who also have brain metastases experienced clinical benefit with fam-trastuzumab deruxtecan-nxki in the phase 2 TUEXEDO-trial.

Single nucleotide polymorphism (SNP) genotyping could be used to predict radiation dermatitis in patients with breast cancer.

Fam-trastuzumab deruxtecan-nxki is now an FDA-approved regimen for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.

Patients who underwent prospective surveillance with bioimpedance spectroscopy were less likely to develop chronic breast cancer–related lymphedema compared with patients who were assessed with tape measure.

Sheila Ridner, PhD, RN, FAAN, discusses the implications of the PREVENT study and how oncology nurses can advocate for patients with breast cancer.

New data demonstrate that regular exercise can help patients with breast cancer mitigate the physical and mental treatment–related side effects that might impact their quality of life.

Charles E. Geyer, MD, FACP, discusses dosing strategies and adverse event management with olaparib.

Oncology Nursing News® speaks with the Charles E. Geyer, MD, FACP, an investigator with the phase 3 OlympiA trial to better understand the significance of olaparib’s approval and to determine what oncology nurses need to know about the new agent.

The PARP inhibitor demonstrated impressive overall survival benefit in patients with BRCA-mutated, HER2-negative, high-risk early breast cancer.

La-Urshala Brock, FNP-BC, CNM, RNFA, discusses effective toxicity management for patients with breast cancer receiving pembrolizumab.

Sheila L. Ridner, PhD, RN, FAAN, provides an overview of bioimpedance spectroscopy and how the simple design allows for standardized subclinical lymphedema surveillance in breast cancer survivors.

Charles L. Loprinzi, MD, discusses the efficacy of agents like gabapentin and olanzapine to combat breast cancer treatment-related pains and speaks to the future of nonestrogenic toxicity management within this space.